Why the study?
Does VCD use improve bleeding, time to hemostasis, and time to ambulation in patients following transfemoral percutaneous coronary intervention?
Does VCD use improve bleeding, time to hemostasis, and time to ambulation in patients following transfemoral percutaneous coronary intervention?
Following transfemoral PCI, vascular closure devices reduce time to hemostasis and ambulation but do not significantly reduce bleeding.
Answers are grounded in this paper and cite their sources.
May shorten hemostasis and ambulation after transfemoral PCI; leaves open whether VCDs reduce bleeding in randomized trials.
<0.01 for both). Conclusions Following transfemoral percutaneous coronary intervention, VCD use is associated with a shorter time to hemostasis and time to ambulation but not less bleeding. Further study of patients with high-bleeding risk is required, including women, patients with chronic kidney disease, and those using high-potency P2Y12 inhibitors. Registration URL: https://clinicaltrials.gov/ct2/show/NCT01848106; Unique identifier: NCT01848106.
No takes yet. Share an insight, caveat, or question.
Marquis‐Gravel et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: